Description
Highlights from EBMT 2025
Article: Highlights from EBMT 2025
€3.03
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in urologic cancer
€3.03 Add to cart -
Article: Highlights in melanoma
€3.03 Add to cart -
Article: INTRODUCTION
€3.03 Add to cart
